nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—SRC—urinary bladder cancer	0.27	0.598	CbGaD
Vandetanib—EGFR—urinary bladder cancer	0.181	0.402	CbGaD
Vandetanib—ABCC1—Epirubicin—urinary bladder cancer	0.0268	0.141	CbGbCtD
Vandetanib—ABCC1—Etoposide—urinary bladder cancer	0.0209	0.11	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—urinary bladder cancer	0.0168	0.088	CbGbCtD
Vandetanib—ABCG2—Carboplatin—urinary bladder cancer	0.0167	0.0875	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—urinary bladder cancer	0.0143	0.0749	CbGbCtD
Vandetanib—ABCG2—Cisplatin—urinary bladder cancer	0.0142	0.0748	CbGbCtD
Vandetanib—ABCG2—Etoposide—urinary bladder cancer	0.014	0.0735	CbGbCtD
Vandetanib—ABCC1—Methotrexate—urinary bladder cancer	0.0138	0.0726	CbGbCtD
Vandetanib—ALB—Fluorouracil—urinary bladder cancer	0.0116	0.0607	CbGbCtD
Vandetanib—CYP3A4—Thiotepa—urinary bladder cancer	0.0111	0.0586	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—urinary bladder cancer	0.00954	0.0501	CbGbCtD
Vandetanib—ABCG2—Methotrexate—urinary bladder cancer	0.00925	0.0486	CbGbCtD
Vandetanib—ALB—Methotrexate—urinary bladder cancer	0.00637	0.0335	CbGbCtD
Vandetanib—CYP3A4—Etoposide—urinary bladder cancer	0.00302	0.0159	CbGbCtD
Vandetanib—FMO3—urine—urinary bladder cancer	0.00217	0.0221	CbGeAlD
Vandetanib—KDR—umbilical vein—urinary bladder cancer	0.00208	0.0211	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00206	0.0108	CbGbCtD
Vandetanib—Afatinib—ERBB2—urinary bladder cancer	0.00192	0.396	CrCbGaD
Vandetanib—PTK6—prostate gland—urinary bladder cancer	0.00153	0.0156	CbGeAlD
Vandetanib—EPHA6—prostate gland—urinary bladder cancer	0.00128	0.013	CbGeAlD
Vandetanib—EPHA5—prostate gland—urinary bladder cancer	0.00118	0.012	CbGeAlD
Vandetanib—BMPR1B—prostate gland—urinary bladder cancer	0.00116	0.0118	CbGeAlD
Vandetanib—PTK6—renal system—urinary bladder cancer	0.00104	0.0106	CbGeAlD
Vandetanib—PTK6—urethra—urinary bladder cancer	0.00103	0.0104	CbGeAlD
Vandetanib—STK35—prostate gland—urinary bladder cancer	0.000987	0.01	CbGeAlD
Vandetanib—ABL2—prostate gland—urinary bladder cancer	0.000962	0.00977	CbGeAlD
Vandetanib—EGFR—prostate gland—urinary bladder cancer	0.000939	0.00953	CbGeAlD
Vandetanib—FLT4—prostate gland—urinary bladder cancer	0.000915	0.00929	CbGeAlD
Vandetanib—Afatinib—EGFR—urinary bladder cancer	0.00091	0.187	CrCbGaD
Vandetanib—RIPK2—prostate gland—urinary bladder cancer	0.00091	0.00924	CbGeAlD
Vandetanib—VEGFA—prostate gland—urinary bladder cancer	0.000907	0.00922	CbGeAlD
Vandetanib—FMO1—prostate gland—urinary bladder cancer	0.000903	0.00917	CbGeAlD
Vandetanib—IRAK4—prostate gland—urinary bladder cancer	0.000888	0.00902	CbGeAlD
Vandetanib—LTK—female reproductive system—urinary bladder cancer	0.000872	0.00886	CbGeAlD
Vandetanib—ERBB3—prostate gland—urinary bladder cancer	0.000871	0.00885	CbGeAlD
Vandetanib—BMPR1B—epithelium—urinary bladder cancer	0.000853	0.00866	CbGeAlD
Vandetanib—PTK6—female reproductive system—urinary bladder cancer	0.000836	0.00849	CbGeAlD
Vandetanib—MKNK1—prostate gland—urinary bladder cancer	0.000818	0.00831	CbGeAlD
Vandetanib—FGR—prostate gland—urinary bladder cancer	0.000808	0.0082	CbGeAlD
Vandetanib—RET—prostate gland—urinary bladder cancer	0.000808	0.0082	CbGeAlD
Vandetanib—LCK—prostate gland—urinary bladder cancer	0.000808	0.0082	CbGeAlD
Vandetanib—AXL—prostate gland—urinary bladder cancer	0.000804	0.00817	CbGeAlD
Vandetanib—FMO3—prostate gland—urinary bladder cancer	0.00078	0.00792	CbGeAlD
Vandetanib—SLK—prostate gland—urinary bladder cancer	0.000774	0.00787	CbGeAlD
Vandetanib—RIPK2—seminal vesicle—urinary bladder cancer	0.00077	0.00782	CbGeAlD
Vandetanib—PTK6—vagina—urinary bladder cancer	0.000756	0.00768	CbGeAlD
Vandetanib—FYN—prostate gland—urinary bladder cancer	0.000753	0.00765	CbGeAlD
Vandetanib—IRAK4—seminal vesicle—urinary bladder cancer	0.000751	0.00763	CbGeAlD
Vandetanib—MAP4K5—prostate gland—urinary bladder cancer	0.000736	0.00747	CbGeAlD
Vandetanib—TEK—prostate gland—urinary bladder cancer	0.000736	0.00747	CbGeAlD
Vandetanib—EPHB6—prostate gland—urinary bladder cancer	0.000703	0.00714	CbGeAlD
Vandetanib—EPHA6—female reproductive system—urinary bladder cancer	0.000697	0.00708	CbGeAlD
Vandetanib—PLK4—female reproductive system—urinary bladder cancer	0.000688	0.00699	CbGeAlD
Vandetanib—FGR—seminal vesicle—urinary bladder cancer	0.000683	0.00694	CbGeAlD
Vandetanib—YES1—prostate gland—urinary bladder cancer	0.000679	0.0069	CbGeAlD
Vandetanib—STK10—prostate gland—urinary bladder cancer	0.000673	0.00684	CbGeAlD
Vandetanib—FLT4—epithelium—urinary bladder cancer	0.000672	0.00683	CbGeAlD
Vandetanib—RIPK2—epithelium—urinary bladder cancer	0.000669	0.00679	CbGeAlD
Vandetanib—SLK—seminal vesicle—urinary bladder cancer	0.000655	0.00665	CbGeAlD
Vandetanib—SRC—prostate gland—urinary bladder cancer	0.000654	0.00664	CbGeAlD
Vandetanib—TYRO3—female reproductive system—urinary bladder cancer	0.000647	0.00657	CbGeAlD
Vandetanib—Erlotinib—EGFR—urinary bladder cancer	0.000643	0.132	CrCbGaD
Vandetanib—VEGFA—smooth muscle tissue—urinary bladder cancer	0.000642	0.00653	CbGeAlD
Vandetanib—ERBB3—epithelium—urinary bladder cancer	0.00064	0.0065	CbGeAlD
Vandetanib—FYN—seminal vesicle—urinary bladder cancer	0.000637	0.00647	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—urinary bladder cancer	0.000633	0.00643	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—urinary bladder cancer	0.000633	0.00643	CbGeAlD
Vandetanib—MAP4K5—seminal vesicle—urinary bladder cancer	0.000622	0.00632	CbGeAlD
Vandetanib—FMO1—renal system—urinary bladder cancer	0.000615	0.00625	CbGeAlD
Vandetanib—RIPK2—urethra—urinary bladder cancer	0.000609	0.00619	CbGeAlD
Vandetanib—VEGFA—urethra—urinary bladder cancer	0.000608	0.00617	CbGeAlD
Vandetanib—FMO1—urethra—urinary bladder cancer	0.000604	0.00614	CbGeAlD
Vandetanib—KDR—prostate gland—urinary bladder cancer	0.000601	0.00611	CbGeAlD
Vandetanib—MAP2K5—prostate gland—urinary bladder cancer	0.000601	0.00611	CbGeAlD
Vandetanib—IRAK4—urethra—urinary bladder cancer	0.000595	0.00604	CbGeAlD
Vandetanib—EPHB6—seminal vesicle—urinary bladder cancer	0.000595	0.00604	CbGeAlD
Vandetanib—ERBB3—renal system—urinary bladder cancer	0.000594	0.00603	CbGeAlD
Vandetanib—RET—epithelium—urinary bladder cancer	0.000593	0.00603	CbGeAlD
Vandetanib—Bosutinib—SRC—urinary bladder cancer	0.00059	0.121	CrCbGaD
Vandetanib—EPHA5—vagina—urinary bladder cancer	0.000585	0.00594	CbGeAlD
Vandetanib—YES1—seminal vesicle—urinary bladder cancer	0.000575	0.00584	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—urinary bladder cancer	0.00057	0.00579	CbGeAlD
Vandetanib—CYP3A4—urine—urinary bladder cancer	0.000568	0.00577	CbGeAlD
Vandetanib—RET—renal system—urinary bladder cancer	0.00055	0.00559	CbGeAlD
Vandetanib—FLT3—female reproductive system—urinary bladder cancer	0.00055	0.00558	CbGeAlD
Vandetanib—MKNK1—urethra—urinary bladder cancer	0.000547	0.00556	CbGeAlD
Vandetanib—LCK—urethra—urinary bladder cancer	0.000541	0.00549	CbGeAlD
Vandetanib—FGR—urethra—urinary bladder cancer	0.000541	0.00549	CbGeAlD
Vandetanib—TEK—epithelium—urinary bladder cancer	0.000541	0.00549	CbGeAlD
Vandetanib—STK35—female reproductive system—urinary bladder cancer	0.000539	0.00547	CbGeAlD
Vandetanib—AXL—urethra—urinary bladder cancer	0.000539	0.00547	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—urinary bladder cancer	0.000533	0.00541	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—urinary bladder cancer	0.000521	0.00529	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—urinary bladder cancer	0.000521	0.00529	CbGeAlD
Vandetanib—PDGFRB—prostate gland—urinary bladder cancer	0.00052	0.00529	CbGeAlD
Vandetanib—SLK—urethra—urinary bladder cancer	0.000518	0.00527	CbGeAlD
Vandetanib—BLK—lymph node—urinary bladder cancer	0.000516	0.00524	CbGeAlD
Vandetanib—FYN—renal system—urinary bladder cancer	0.000513	0.00521	CbGeAlD
Vandetanib—LTK—lymph node—urinary bladder cancer	0.00051	0.00518	CbGeAlD
Vandetanib—MAP2K5—seminal vesicle—urinary bladder cancer	0.000509	0.00517	CbGeAlD
Vandetanib—KDR—seminal vesicle—urinary bladder cancer	0.000509	0.00517	CbGeAlD
Vandetanib—FYN—urethra—urinary bladder cancer	0.000504	0.00512	CbGeAlD
Vandetanib—TEK—renal system—urinary bladder cancer	0.000501	0.00509	CbGeAlD
Vandetanib—FLT4—female reproductive system—urinary bladder cancer	0.000499	0.00507	CbGeAlD
Vandetanib—RIPK2—female reproductive system—urinary bladder cancer	0.000497	0.00504	CbGeAlD
Vandetanib—MAP4K5—urethra—urinary bladder cancer	0.000493	0.005	CbGeAlD
Vandetanib—TEK—urethra—urinary bladder cancer	0.000493	0.005	CbGeAlD
Vandetanib—ORM1—prostate gland—urinary bladder cancer	0.000488	0.00496	CbGeAlD
Vandetanib—STK35—vagina—urinary bladder cancer	0.000487	0.00495	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—urinary bladder cancer	0.000481	0.00489	CbGeAlD
Vandetanib—SRC—epithelium—urinary bladder cancer	0.00048	0.00488	CbGeAlD
Vandetanib—ERBB3—female reproductive system—urinary bladder cancer	0.000475	0.00483	CbGeAlD
Vandetanib—ABL2—vagina—urinary bladder cancer	0.000475	0.00482	CbGeAlD
Vandetanib—EPHB6—urethra—urinary bladder cancer	0.000471	0.00478	CbGeAlD
Vandetanib—ABL1—prostate gland—urinary bladder cancer	0.000464	0.00471	CbGeAlD
Vandetanib—YES1—renal system—urinary bladder cancer	0.000463	0.0047	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—urinary bladder cancer	0.000463	0.0047	CbGeAlD
Vandetanib—STK10—renal system—urinary bladder cancer	0.000459	0.00466	CbGeAlD
Vandetanib—YES1—urethra—urinary bladder cancer	0.000455	0.00462	CbGeAlD
Vandetanib—RIPK2—vagina—urinary bladder cancer	0.000449	0.00456	CbGeAlD
Vandetanib—VEGFA—vagina—urinary bladder cancer	0.000448	0.00455	CbGeAlD
Vandetanib—MKNK1—female reproductive system—urinary bladder cancer	0.000446	0.00453	CbGeAlD
Vandetanib—FMO1—vagina—urinary bladder cancer	0.000446	0.00453	CbGeAlD
Vandetanib—SRC—renal system—urinary bladder cancer	0.000446	0.00453	CbGeAlD
Vandetanib—KDR—epithelium—urinary bladder cancer	0.000442	0.00449	CbGeAlD
Vandetanib—FGR—female reproductive system—urinary bladder cancer	0.000441	0.00448	CbGeAlD
Vandetanib—PDGFRB—seminal vesicle—urinary bladder cancer	0.00044	0.00447	CbGeAlD
Vandetanib—AXL—female reproductive system—urinary bladder cancer	0.000439	0.00446	CbGeAlD
Vandetanib—IRAK4—vagina—urinary bladder cancer	0.000439	0.00446	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—urinary bladder cancer	0.000426	0.00432	CbGeAlD
Vandetanib—FYN—female reproductive system—urinary bladder cancer	0.000411	0.00417	CbGeAlD
Vandetanib—KDR—renal system—urinary bladder cancer	0.00041	0.00416	CbGeAlD
Vandetanib—MKNK1—vagina—urinary bladder cancer	0.000404	0.0041	CbGeAlD
Vandetanib—PLK4—lymph node—urinary bladder cancer	0.000403	0.00409	CbGeAlD
Vandetanib—MAP2K5—urethra—urinary bladder cancer	0.000403	0.00409	CbGeAlD
Vandetanib—KDR—urethra—urinary bladder cancer	0.000403	0.00409	CbGeAlD
Vandetanib—Gefitinib—EGFR—urinary bladder cancer	0.000402	0.0827	CrCbGaD
Vandetanib—TEK—female reproductive system—urinary bladder cancer	0.000402	0.00408	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—urinary bladder cancer	0.000402	0.00408	CbGeAlD
Vandetanib—FGR—vagina—urinary bladder cancer	0.000399	0.00405	CbGeAlD
Vandetanib—LCK—vagina—urinary bladder cancer	0.000399	0.00405	CbGeAlD
Vandetanib—AXL—vagina—urinary bladder cancer	0.000397	0.00403	CbGeAlD
Vandetanib—Bosutinib—EGFR—urinary bladder cancer	0.000396	0.0814	CrCbGaD
Vandetanib—ABL1—seminal vesicle—urinary bladder cancer	0.000392	0.00399	CbGeAlD
Vandetanib—FMO3—vagina—urinary bladder cancer	0.000385	0.00391	CbGeAlD
Vandetanib—PDGFRB—epithelium—urinary bladder cancer	0.000382	0.00388	CbGeAlD
Vandetanib—SLK—vagina—urinary bladder cancer	0.000382	0.00388	CbGeAlD
Vandetanib—FYN—vagina—urinary bladder cancer	0.000372	0.00378	CbGeAlD
Vandetanib—YES1—female reproductive system—urinary bladder cancer	0.000371	0.00377	CbGeAlD
Vandetanib—BMPR1B—lymph node—urinary bladder cancer	0.000371	0.00376	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.000368	0.00374	CbGeAlD
Vandetanib—STK10—female reproductive system—urinary bladder cancer	0.000368	0.00373	CbGeAlD
Vandetanib—MAP4K5—vagina—urinary bladder cancer	0.000363	0.00369	CbGeAlD
Vandetanib—SRC—female reproductive system—urinary bladder cancer	0.000357	0.00362	CbGeAlD
Vandetanib—PDGFRB—renal system—urinary bladder cancer	0.000355	0.0036	CbGeAlD
Vandetanib—ABCC1—prostate gland—urinary bladder cancer	0.000353	0.00359	CbGeAlD
Vandetanib—PDGFRB—urethra—urinary bladder cancer	0.000348	0.00354	CbGeAlD
Vandetanib—EPHB6—vagina—urinary bladder cancer	0.000347	0.00353	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Valrubicin—urinary bladder cancer	0.000344	0.0915	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Valrubicin—urinary bladder cancer	0.000344	0.0915	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Valrubicin—urinary bladder cancer	0.000344	0.0915	CbGdCrCtD
Vandetanib—YES1—vagina—urinary bladder cancer	0.000335	0.00341	CbGeAlD
Vandetanib—STK10—vagina—urinary bladder cancer	0.000332	0.00338	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000328	0.00334	CbGeAlD
Vandetanib—KDR—female reproductive system—urinary bladder cancer	0.000328	0.00333	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—urinary bladder cancer	0.000328	0.00333	CbGeAlD
Vandetanib—FLT3—lymph node—urinary bladder cancer	0.000322	0.00327	CbGeAlD
Vandetanib—ABL1—renal system—urinary bladder cancer	0.000316	0.00321	CbGeAlD
Vandetanib—STK35—lymph node—urinary bladder cancer	0.000315	0.0032	CbGeAlD
Vandetanib—ABL1—urethra—urinary bladder cancer	0.000311	0.00315	CbGeAlD
Vandetanib—ABL2—lymph node—urinary bladder cancer	0.000307	0.00312	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—urinary bladder cancer	0.0003	0.0796	CbGdCrCtD
Vandetanib—EGFR—lymph node—urinary bladder cancer	0.0003	0.00304	CbGeAlD
Vandetanib—ABCC1—seminal vesicle—urinary bladder cancer	0.000299	0.00304	CbGeAlD
Vandetanib—KDR—vagina—urinary bladder cancer	0.000297	0.00302	CbGeAlD
Vandetanib—MAP2K5—vagina—urinary bladder cancer	0.000297	0.00302	CbGeAlD
Vandetanib—ABCG2—prostate gland—urinary bladder cancer	0.000293	0.00297	CbGeAlD
Vandetanib—FLT4—lymph node—urinary bladder cancer	0.000292	0.00297	CbGeAlD
Vandetanib—RIPK2—lymph node—urinary bladder cancer	0.000291	0.00295	CbGeAlD
Vandetanib—VEGFA—lymph node—urinary bladder cancer	0.00029	0.00294	CbGeAlD
Vandetanib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.00029	0.0769	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.00029	0.0769	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.00029	0.0769	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.00029	0.0769	CbGdCrCtD
Vandetanib—FMO1—lymph node—urinary bladder cancer	0.000288	0.00293	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—urinary bladder cancer	0.000284	0.00289	CbGeAlD
Vandetanib—IRAK4—lymph node—urinary bladder cancer	0.000284	0.00288	CbGeAlD
Vandetanib—ERBB3—lymph node—urinary bladder cancer	0.000278	0.00282	CbGeAlD
Vandetanib—ORM1—female reproductive system—urinary bladder cancer	0.000266	0.00271	CbGeAlD
Vandetanib—MKNK1—lymph node—urinary bladder cancer	0.000261	0.00265	CbGeAlD
Vandetanib—LCK—lymph node—urinary bladder cancer	0.000258	0.00262	CbGeAlD
Vandetanib—FGR—lymph node—urinary bladder cancer	0.000258	0.00262	CbGeAlD
Vandetanib—RET—lymph node—urinary bladder cancer	0.000258	0.00262	CbGeAlD
Vandetanib—PDGFRB—vagina—urinary bladder cancer	0.000257	0.00261	CbGeAlD
Vandetanib—AXL—lymph node—urinary bladder cancer	0.000257	0.00261	CbGeAlD
Vandetanib—ABL1—female reproductive system—urinary bladder cancer	0.000253	0.00257	CbGeAlD
Vandetanib—FMO3—lymph node—urinary bladder cancer	0.000249	0.00253	CbGeAlD
Vandetanib—ABCG2—seminal vesicle—urinary bladder cancer	0.000247	0.00251	CbGeAlD
Vandetanib—SLK—lymph node—urinary bladder cancer	0.000247	0.00251	CbGeAlD
Vandetanib—FYN—lymph node—urinary bladder cancer	0.00024	0.00244	CbGeAlD
Vandetanib—ABCC1—urethra—urinary bladder cancer	0.000237	0.0024	CbGeAlD
Vandetanib—TEK—lymph node—urinary bladder cancer	0.000235	0.00239	CbGeAlD
Vandetanib—MAP4K5—lymph node—urinary bladder cancer	0.000235	0.00239	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—urinary bladder cancer	0.00023	0.061	CbGdCrCtD
Vandetanib—ABL1—vagina—urinary bladder cancer	0.000229	0.00233	CbGeAlD
Vandetanib—EPHB6—lymph node—urinary bladder cancer	0.000225	0.00228	CbGeAlD
Vandetanib—YES1—lymph node—urinary bladder cancer	0.000217	0.0022	CbGeAlD
Vandetanib—STK10—lymph node—urinary bladder cancer	0.000215	0.00218	CbGeAlD
Vandetanib—SRC—lymph node—urinary bladder cancer	0.000209	0.00212	CbGeAlD
Vandetanib—ABCG2—urethra—urinary bladder cancer	0.000196	0.00199	CbGeAlD
Vandetanib—KDR—lymph node—urinary bladder cancer	0.000192	0.00195	CbGeAlD
Vandetanib—MAP2K5—lymph node—urinary bladder cancer	0.000192	0.00195	CbGeAlD
Vandetanib—ABCC1—vagina—urinary bladder cancer	0.000174	0.00177	CbGeAlD
Vandetanib—PDGFRB—lymph node—urinary bladder cancer	0.000166	0.00169	CbGeAlD
Vandetanib—ORM1—lymph node—urinary bladder cancer	0.000156	0.00158	CbGeAlD
Vandetanib—ABL1—lymph node—urinary bladder cancer	0.000148	0.0015	CbGeAlD
Vandetanib—ABCG2—vagina—urinary bladder cancer	0.000144	0.00147	CbGeAlD
Vandetanib—CYP3A4—renal system—urinary bladder cancer	0.000139	0.00141	CbGeAlD
Vandetanib—ALB—lymph node—urinary bladder cancer	0.000137	0.00139	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—urinary bladder cancer	0.00012	0.0318	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—urinary bladder cancer	0.00012	0.0318	CbGdCrCtD
Vandetanib—ABCC1—lymph node—urinary bladder cancer	0.000113	0.00115	CbGeAlD
Vandetanib—CYP3A4—female reproductive system—urinary bladder cancer	0.000111	0.00113	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—urinary bladder cancer	0.000111	0.0295	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—urinary bladder cancer	0.000111	0.0295	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000101	0.0268	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	0.000101	0.0268	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000101	0.0268	CbGdCrCtD
Vandetanib—ABCG2—lymph node—urinary bladder cancer	9.34e-05	0.000949	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	9.33e-05	0.0248	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	9.33e-05	0.0248	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	9.33e-05	0.0248	CbGdCrCtD
Vandetanib—Renal failure—Methotrexate—urinary bladder cancer	8.47e-05	0.000772	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—urinary bladder cancer	8.46e-05	0.000771	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—urinary bladder cancer	8.46e-05	0.000771	CcSEcCtD
Vandetanib—Dizziness—Thiotepa—urinary bladder cancer	8.45e-05	0.00077	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	8.41e-05	0.000766	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—urinary bladder cancer	8.4e-05	0.000765	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—urinary bladder cancer	8.38e-05	0.000763	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—urinary bladder cancer	8.37e-05	0.000763	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—urinary bladder cancer	8.37e-05	0.000763	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—urinary bladder cancer	8.36e-05	0.000761	CcSEcCtD
Vandetanib—Body temperature increased—Fluorouracil—urinary bladder cancer	8.35e-05	0.000761	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—urinary bladder cancer	8.26e-05	0.000752	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—urinary bladder cancer	8.24e-05	0.000751	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—urinary bladder cancer	8.22e-05	0.000749	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—urinary bladder cancer	8.21e-05	0.000748	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—urinary bladder cancer	8.18e-05	0.000746	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—urinary bladder cancer	8.18e-05	0.000746	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—urinary bladder cancer	8.16e-05	0.000744	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	8.15e-05	0.000743	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—urinary bladder cancer	8.13e-05	0.000741	CcSEcCtD
Vandetanib—Vomiting—Thiotepa—urinary bladder cancer	8.12e-05	0.00074	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—urinary bladder cancer	8.11e-05	0.000739	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—urinary bladder cancer	8.07e-05	0.000735	CcSEcCtD
Vandetanib—Infestation—Epirubicin—urinary bladder cancer	8.07e-05	0.000735	CcSEcCtD
Vandetanib—Rash—Thiotepa—urinary bladder cancer	8.05e-05	0.000734	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—urinary bladder cancer	8.05e-05	0.000733	CcSEcCtD
Vandetanib—Dermatitis—Thiotepa—urinary bladder cancer	8.05e-05	0.000733	CcSEcCtD
Vandetanib—Headache—Thiotepa—urinary bladder cancer	8e-05	0.000729	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	8e-05	0.000729	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—urinary bladder cancer	7.98e-05	0.000727	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—urinary bladder cancer	7.93e-05	0.000722	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	7.92e-05	0.000722	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—urinary bladder cancer	7.92e-05	0.000722	CcSEcCtD
Vandetanib—Fatigue—Etoposide—urinary bladder cancer	7.91e-05	0.000721	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—urinary bladder cancer	7.86e-05	0.000716	CcSEcCtD
Vandetanib—Pain—Etoposide—urinary bladder cancer	7.85e-05	0.000715	CcSEcCtD
Vandetanib—Constipation—Etoposide—urinary bladder cancer	7.85e-05	0.000715	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—urinary bladder cancer	7.84e-05	0.000714	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—urinary bladder cancer	7.84e-05	0.000714	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—urinary bladder cancer	7.83e-05	0.000713	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—urinary bladder cancer	7.83e-05	0.000713	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	7.78e-05	0.000709	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—urinary bladder cancer	7.78e-05	0.000709	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—urinary bladder cancer	7.74e-05	0.000705	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—urinary bladder cancer	7.73e-05	0.000705	CcSEcCtD
Vandetanib—Asthenia—Gemcitabine—urinary bladder cancer	7.71e-05	0.000703	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—urinary bladder cancer	7.69e-05	0.000701	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—urinary bladder cancer	7.64e-05	0.000696	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	7.64e-05	0.000696	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	7.63e-05	0.000695	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—urinary bladder cancer	7.61e-05	0.000693	CcSEcCtD
Vandetanib—Pruritus—Gemcitabine—urinary bladder cancer	7.6e-05	0.000693	CcSEcCtD
Vandetanib—Nausea—Thiotepa—urinary bladder cancer	7.59e-05	0.000691	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—urinary bladder cancer	7.58e-05	0.000691	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—urinary bladder cancer	7.57e-05	0.00069	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—urinary bladder cancer	7.57e-05	0.00069	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	7.55e-05	0.000688	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—urinary bladder cancer	7.51e-05	0.000684	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—urinary bladder cancer	7.5e-05	0.000684	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—urinary bladder cancer	7.48e-05	0.000681	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—urinary bladder cancer	7.46e-05	0.00068	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—urinary bladder cancer	7.46e-05	0.00068	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—urinary bladder cancer	7.46e-05	0.000679	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	7.4e-05	0.000674	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—urinary bladder cancer	7.37e-05	0.000672	CcSEcCtD
Vandetanib—Diarrhoea—Gemcitabine—urinary bladder cancer	7.35e-05	0.00067	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—urinary bladder cancer	7.34e-05	0.000668	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—urinary bladder cancer	7.32e-05	0.000667	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—urinary bladder cancer	7.28e-05	0.000663	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—urinary bladder cancer	7.27e-05	0.000663	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—urinary bladder cancer	7.25e-05	0.000661	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—urinary bladder cancer	7.25e-05	0.000661	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.25e-05	0.000661	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.25e-05	0.000661	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—urinary bladder cancer	7.24e-05	0.00066	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—urinary bladder cancer	7.23e-05	0.000659	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—urinary bladder cancer	7.23e-05	0.000659	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—urinary bladder cancer	7.19e-05	0.000655	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—urinary bladder cancer	7.18e-05	0.000654	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.15e-05	0.000652	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—urinary bladder cancer	7.12e-05	0.000648	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—urinary bladder cancer	7.1e-05	0.000647	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.06e-05	0.000643	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—urinary bladder cancer	7.04e-05	0.000641	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—urinary bladder cancer	7.02e-05	0.00064	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—urinary bladder cancer	7e-05	0.000638	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—urinary bladder cancer	6.99e-05	0.000637	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—urinary bladder cancer	6.98e-05	0.000636	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—urinary bladder cancer	6.97e-05	0.000635	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—urinary bladder cancer	6.85e-05	0.000625	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—urinary bladder cancer	6.85e-05	0.000624	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—urinary bladder cancer	6.84e-05	0.000623	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—urinary bladder cancer	6.83e-05	0.000623	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—urinary bladder cancer	6.82e-05	0.000621	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—urinary bladder cancer	6.78e-05	0.000618	CcSEcCtD
Vandetanib—Rash—Gemcitabine—urinary bladder cancer	6.78e-05	0.000617	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—urinary bladder cancer	6.77e-05	0.000617	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—urinary bladder cancer	6.77e-05	0.000617	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—urinary bladder cancer	6.73e-05	0.000614	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—urinary bladder cancer	6.73e-05	0.000614	CcSEcCtD
Vandetanib—Headache—Gemcitabine—urinary bladder cancer	6.73e-05	0.000613	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—urinary bladder cancer	6.72e-05	0.000612	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—urinary bladder cancer	6.72e-05	0.000612	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—urinary bladder cancer	6.7e-05	0.00061	CcSEcCtD
Vandetanib—Rash—Fluorouracil—urinary bladder cancer	6.66e-05	0.000607	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—urinary bladder cancer	6.66e-05	0.000607	CcSEcCtD
Vandetanib—Headache—Fluorouracil—urinary bladder cancer	6.62e-05	0.000603	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	6.62e-05	0.000603	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—urinary bladder cancer	6.6e-05	0.000601	CcSEcCtD
Vandetanib—Asthenia—Etoposide—urinary bladder cancer	6.58e-05	0.0006	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—urinary bladder cancer	6.57e-05	0.000599	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—urinary bladder cancer	6.57e-05	0.000598	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—urinary bladder cancer	6.53e-05	0.000595	CcSEcCtD
Vandetanib—Pruritus—Etoposide—urinary bladder cancer	6.49e-05	0.000592	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—urinary bladder cancer	6.47e-05	0.000589	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—urinary bladder cancer	6.46e-05	0.000588	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—urinary bladder cancer	6.4e-05	0.000583	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—urinary bladder cancer	6.38e-05	0.000582	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—urinary bladder cancer	6.37e-05	0.00058	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—urinary bladder cancer	6.35e-05	0.000578	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—urinary bladder cancer	6.34e-05	0.000578	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.33e-05	0.000577	CcSEcCtD
Vandetanib—Rash—Cisplatin—urinary bladder cancer	6.32e-05	0.000576	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—urinary bladder cancer	6.31e-05	0.000575	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—urinary bladder cancer	6.3e-05	0.000574	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—urinary bladder cancer	6.28e-05	0.000572	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—urinary bladder cancer	6.28e-05	0.000572	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—urinary bladder cancer	6.26e-05	0.00057	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—urinary bladder cancer	6.22e-05	0.000567	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—urinary bladder cancer	6.17e-05	0.000562	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—urinary bladder cancer	6.08e-05	0.000554	CcSEcCtD
Vandetanib—Dizziness—Etoposide—urinary bladder cancer	6.07e-05	0.000553	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—urinary bladder cancer	6.06e-05	0.000552	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	6.04e-05	0.00055	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—urinary bladder cancer	5.98e-05	0.000545	CcSEcCtD
Vandetanib—Nausea—Cisplatin—urinary bladder cancer	5.95e-05	0.000542	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—urinary bladder cancer	5.94e-05	0.000541	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—urinary bladder cancer	5.92e-05	0.000539	CcSEcCtD
Vandetanib—Cough—Methotrexate—urinary bladder cancer	5.88e-05	0.000536	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—urinary bladder cancer	5.87e-05	0.000535	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—urinary bladder cancer	5.84e-05	0.000532	CcSEcCtD
Vandetanib—Vomiting—Etoposide—urinary bladder cancer	5.83e-05	0.000532	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—urinary bladder cancer	5.83e-05	0.000531	CcSEcCtD
Vandetanib—Rash—Etoposide—urinary bladder cancer	5.79e-05	0.000527	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—urinary bladder cancer	5.78e-05	0.000527	CcSEcCtD
Vandetanib—Headache—Etoposide—urinary bladder cancer	5.75e-05	0.000524	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—urinary bladder cancer	5.73e-05	0.000522	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—urinary bladder cancer	5.73e-05	0.000522	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—urinary bladder cancer	5.71e-05	0.00052	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.69e-05	0.000519	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—urinary bladder cancer	5.61e-05	0.000511	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—urinary bladder cancer	5.54e-05	0.000505	CcSEcCtD
Vandetanib—Cough—Epirubicin—urinary bladder cancer	5.5e-05	0.000501	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—urinary bladder cancer	5.5e-05	0.000501	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—urinary bladder cancer	5.46e-05	0.000498	CcSEcCtD
Vandetanib—Infection—Methotrexate—urinary bladder cancer	5.46e-05	0.000498	CcSEcCtD
Vandetanib—Nausea—Etoposide—urinary bladder cancer	5.45e-05	0.000497	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—urinary bladder cancer	5.44e-05	0.000496	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—urinary bladder cancer	5.39e-05	0.000491	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.38e-05	0.00049	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—urinary bladder cancer	5.37e-05	0.000489	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—urinary bladder cancer	5.37e-05	0.000489	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—urinary bladder cancer	5.35e-05	0.000487	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—urinary bladder cancer	5.34e-05	0.000487	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.33e-05	0.000486	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—urinary bladder cancer	5.25e-05	0.000478	CcSEcCtD
Vandetanib—Oedema—Epirubicin—urinary bladder cancer	5.14e-05	0.000469	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.13e-05	0.000467	CcSEcCtD
Vandetanib—Infection—Epirubicin—urinary bladder cancer	5.11e-05	0.000466	CcSEcCtD
Vandetanib—Cough—Doxorubicin—urinary bladder cancer	5.09e-05	0.000464	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—urinary bladder cancer	5.05e-05	0.00046	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—urinary bladder cancer	5.04e-05	0.00046	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.04e-05	0.000459	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—urinary bladder cancer	5.03e-05	0.000459	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.01e-05	0.000456	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—urinary bladder cancer	5e-05	0.000455	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—urinary bladder cancer	4.97e-05	0.000453	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—urinary bladder cancer	4.96e-05	0.000452	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—urinary bladder cancer	4.96e-05	0.000452	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—urinary bladder cancer	4.95e-05	0.000451	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—urinary bladder cancer	4.94e-05	0.00045	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.93e-05	0.000449	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—urinary bladder cancer	4.9e-05	0.000447	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—urinary bladder cancer	4.86e-05	0.000442	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—urinary bladder cancer	4.84e-05	0.000441	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—urinary bladder cancer	4.78e-05	0.000435	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—urinary bladder cancer	4.76e-05	0.000434	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.75e-05	0.000432	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—urinary bladder cancer	4.74e-05	0.000432	CcSEcCtD
Vandetanib—Infection—Doxorubicin—urinary bladder cancer	4.73e-05	0.000431	CcSEcCtD
Vandetanib—Pain—Methotrexate—urinary bladder cancer	4.7e-05	0.000428	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.69e-05	0.000427	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.67e-05	0.000425	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.66e-05	0.000425	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—urinary bladder cancer	4.65e-05	0.000424	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—urinary bladder cancer	4.62e-05	0.000421	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—urinary bladder cancer	4.62e-05	0.000421	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—urinary bladder cancer	4.59e-05	0.000418	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—urinary bladder cancer	4.53e-05	0.000413	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.49e-05	0.00041	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—urinary bladder cancer	4.47e-05	0.000407	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.44e-05	0.000405	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—urinary bladder cancer	4.43e-05	0.000404	CcSEcCtD
Vandetanib—Pain—Epirubicin—urinary bladder cancer	4.4e-05	0.000401	CcSEcCtD
Vandetanib—Constipation—Epirubicin—urinary bladder cancer	4.4e-05	0.000401	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—urinary bladder cancer	4.35e-05	0.000396	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—urinary bladder cancer	4.35e-05	0.000396	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.34e-05	0.000395	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—urinary bladder cancer	4.3e-05	0.000392	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—urinary bladder cancer	4.27e-05	0.000389	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—urinary bladder cancer	4.24e-05	0.000387	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.21e-05	0.000383	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—urinary bladder cancer	4.19e-05	0.000382	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—urinary bladder cancer	4.14e-05	0.000377	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.11e-05	0.000374	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—urinary bladder cancer	4.1e-05	0.000374	CcSEcCtD
Vandetanib—Pain—Doxorubicin—urinary bladder cancer	4.07e-05	0.000371	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—urinary bladder cancer	4.07e-05	0.000371	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—urinary bladder cancer	4.07e-05	0.000371	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—urinary bladder cancer	4.07e-05	0.000371	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—urinary bladder cancer	3.94e-05	0.000359	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.89e-05	0.000355	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—urinary bladder cancer	3.89e-05	0.000354	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—urinary bladder cancer	3.76e-05	0.000343	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—urinary bladder cancer	3.76e-05	0.000343	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—urinary bladder cancer	3.76e-05	0.000343	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—urinary bladder cancer	3.69e-05	0.000336	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—urinary bladder cancer	3.64e-05	0.000332	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—urinary bladder cancer	3.63e-05	0.000331	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—urinary bladder cancer	3.52e-05	0.000321	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—urinary bladder cancer	3.49e-05	0.000318	CcSEcCtD
Vandetanib—Rash—Methotrexate—urinary bladder cancer	3.47e-05	0.000316	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—urinary bladder cancer	3.46e-05	0.000316	CcSEcCtD
Vandetanib—Headache—Methotrexate—urinary bladder cancer	3.44e-05	0.000314	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—urinary bladder cancer	3.41e-05	0.000311	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—urinary bladder cancer	3.4e-05	0.00031	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—urinary bladder cancer	3.37e-05	0.000307	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—urinary bladder cancer	3.27e-05	0.000298	CcSEcCtD
Vandetanib—Nausea—Methotrexate—urinary bladder cancer	3.26e-05	0.000298	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—urinary bladder cancer	3.26e-05	0.000297	CcSEcCtD
Vandetanib—Rash—Epirubicin—urinary bladder cancer	3.24e-05	0.000296	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—urinary bladder cancer	3.24e-05	0.000295	CcSEcCtD
Vandetanib—Headache—Epirubicin—urinary bladder cancer	3.22e-05	0.000294	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—urinary bladder cancer	3.15e-05	0.000287	CcSEcCtD
Vandetanib—Nausea—Epirubicin—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—urinary bladder cancer	3.03e-05	0.000276	CcSEcCtD
Vandetanib—Rash—Doxorubicin—urinary bladder cancer	3e-05	0.000273	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—urinary bladder cancer	3e-05	0.000273	CcSEcCtD
Vandetanib—Headache—Doxorubicin—urinary bladder cancer	2.98e-05	0.000272	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—urinary bladder cancer	2.83e-05	0.000258	CcSEcCtD
Vandetanib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.5e-06	1.76e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EP300—urinary bladder cancer	2.49e-06	1.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CDKN1A—urinary bladder cancer	2.48e-06	1.75e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—urinary bladder cancer	2.48e-06	1.75e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERBB2—urinary bladder cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PTEN—urinary bladder cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—RHOA—urinary bladder cancer	2.47e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	2.46e-06	1.74e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—SRC—urinary bladder cancer	2.45e-06	1.73e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.45e-06	1.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TERT—urinary bladder cancer	2.45e-06	1.72e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTP1—urinary bladder cancer	2.44e-06	1.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RHOA—urinary bladder cancer	2.43e-06	1.71e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CDKN1A—urinary bladder cancer	2.43e-06	1.71e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTEN—urinary bladder cancer	2.42e-06	1.71e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—urinary bladder cancer	2.42e-06	1.71e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SRC—urinary bladder cancer	2.42e-06	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—urinary bladder cancer	2.42e-06	1.7e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—urinary bladder cancer	2.42e-06	1.7e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EP300—urinary bladder cancer	2.41e-06	1.7e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CDKN1A—urinary bladder cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—urinary bladder cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTEN—urinary bladder cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RHOA—urinary bladder cancer	2.38e-06	1.68e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—urinary bladder cancer	2.37e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—urinary bladder cancer	2.37e-06	1.67e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—urinary bladder cancer	2.36e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.36e-06	1.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EP300—urinary bladder cancer	2.36e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—urinary bladder cancer	2.35e-06	1.66e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RHOA—urinary bladder cancer	2.35e-06	1.65e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SRC—urinary bladder cancer	2.34e-06	1.65e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—urinary bladder cancer	2.34e-06	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—urinary bladder cancer	2.33e-06	1.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.33e-06	1.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EP300—urinary bladder cancer	2.31e-06	1.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—SRC—urinary bladder cancer	2.3e-06	1.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CDKN1A—urinary bladder cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—urinary bladder cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—urinary bladder cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—urinary bladder cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—urinary bladder cancer	2.28e-06	1.61e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—urinary bladder cancer	2.28e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EP300—urinary bladder cancer	2.28e-06	1.6e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—urinary bladder cancer	2.27e-06	1.6e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TYMS—urinary bladder cancer	2.27e-06	1.6e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	2.25e-06	1.59e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SRC—urinary bladder cancer	2.25e-06	1.58e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR3—urinary bladder cancer	2.25e-06	1.58e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—urinary bladder cancer	2.24e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NCOR1—urinary bladder cancer	2.24e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—urinary bladder cancer	2.24e-06	1.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	2.24e-06	1.58e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—urinary bladder cancer	2.24e-06	1.57e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—urinary bladder cancer	2.23e-06	1.57e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—urinary bladder cancer	2.23e-06	1.57e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—urinary bladder cancer	2.23e-06	1.57e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—urinary bladder cancer	2.23e-06	1.57e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—urinary bladder cancer	2.22e-06	1.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	2.21e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—SRC—urinary bladder cancer	2.21e-06	1.56e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—urinary bladder cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CDKN1A—urinary bladder cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—urinary bladder cancer	2.2e-06	1.55e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—urinary bladder cancer	2.2e-06	1.55e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—urinary bladder cancer	2.2e-06	1.55e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—urinary bladder cancer	2.18e-06	1.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—urinary bladder cancer	2.18e-06	1.54e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—urinary bladder cancer	2.17e-06	1.53e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—urinary bladder cancer	2.17e-06	1.53e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	2.16e-06	1.52e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—urinary bladder cancer	2.15e-06	1.51e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—urinary bladder cancer	2.15e-06	1.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	2.14e-06	1.51e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	2.13e-06	1.5e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—urinary bladder cancer	2.13e-06	1.5e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—urinary bladder cancer	2.12e-06	1.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SRC—urinary bladder cancer	2.12e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDKN1A—urinary bladder cancer	2.12e-06	1.49e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.12e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—urinary bladder cancer	2.11e-06	1.49e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ERCC2—urinary bladder cancer	2.11e-06	1.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—urinary bladder cancer	2.11e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—urinary bladder cancer	2.1e-06	1.48e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—urinary bladder cancer	2.1e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	2.09e-06	1.47e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—urinary bladder cancer	2.09e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	2.08e-06	1.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—urinary bladder cancer	2.06e-06	1.45e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—urinary bladder cancer	2.05e-06	1.44e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	2.05e-06	1.44e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	2.04e-06	1.44e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—urinary bladder cancer	2.04e-06	1.44e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	2.04e-06	1.43e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—urinary bladder cancer	2.03e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—urinary bladder cancer	2.03e-06	1.43e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	2.03e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—urinary bladder cancer	2.02e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—urinary bladder cancer	2.01e-06	1.42e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—urinary bladder cancer	2.01e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—urinary bladder cancer	2e-06	1.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	1.99e-06	1.4e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—urinary bladder cancer	1.98e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—urinary bladder cancer	1.98e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—urinary bladder cancer	1.97e-06	1.39e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—urinary bladder cancer	1.97e-06	1.39e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—urinary bladder cancer	1.96e-06	1.38e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.96e-06	1.38e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.96e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1A—urinary bladder cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—urinary bladder cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.95e-06	1.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—urinary bladder cancer	1.94e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—urinary bladder cancer	1.94e-06	1.37e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—urinary bladder cancer	1.94e-06	1.36e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—urinary bladder cancer	1.94e-06	1.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	1.93e-06	1.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	1.93e-06	1.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	1.92e-06	1.35e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—urinary bladder cancer	1.92e-06	1.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CREBBP—urinary bladder cancer	1.91e-06	1.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—urinary bladder cancer	1.9e-06	1.34e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.9e-06	1.34e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—urinary bladder cancer	1.9e-06	1.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—urinary bladder cancer	1.9e-06	1.34e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—urinary bladder cancer	1.9e-06	1.34e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	1.89e-06	1.33e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—urinary bladder cancer	1.89e-06	1.33e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—urinary bladder cancer	1.89e-06	1.33e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.89e-06	1.33e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	1.88e-06	1.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	1.88e-06	1.32e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—urinary bladder cancer	1.88e-06	1.32e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—urinary bladder cancer	1.87e-06	1.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—urinary bladder cancer	1.86e-06	1.31e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—urinary bladder cancer	1.86e-06	1.31e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—urinary bladder cancer	1.86e-06	1.31e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—urinary bladder cancer	1.86e-06	1.31e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—urinary bladder cancer	1.86e-06	1.31e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—urinary bladder cancer	1.85e-06	1.3e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	1.83e-06	1.29e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—urinary bladder cancer	1.83e-06	1.29e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—urinary bladder cancer	1.83e-06	1.29e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	1.81e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—urinary bladder cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—urinary bladder cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—urinary bladder cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—urinary bladder cancer	1.78e-06	1.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	1.78e-06	1.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	1.78e-06	1.25e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—urinary bladder cancer	1.78e-06	1.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	1.77e-06	1.25e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—urinary bladder cancer	1.77e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—urinary bladder cancer	1.76e-06	1.24e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.75e-06	1.23e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RHOA—urinary bladder cancer	1.73e-06	1.22e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—urinary bladder cancer	1.73e-06	1.22e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—urinary bladder cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—urinary bladder cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—urinary bladder cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—urinary bladder cancer	1.71e-06	1.2e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—urinary bladder cancer	1.7e-06	1.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—urinary bladder cancer	1.7e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—urinary bladder cancer	1.69e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	1.66e-06	1.17e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—urinary bladder cancer	1.65e-06	1.16e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—urinary bladder cancer	1.64e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—urinary bladder cancer	1.62e-06	1.14e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—urinary bladder cancer	1.62e-06	1.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—urinary bladder cancer	1.62e-06	1.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	1.61e-06	1.13e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—urinary bladder cancer	1.61e-06	1.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—urinary bladder cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—urinary bladder cancer	1.58e-06	1.12e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—urinary bladder cancer	1.58e-06	1.11e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.58e-06	1.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—urinary bladder cancer	1.56e-06	1.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	1.56e-06	1.1e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—urinary bladder cancer	1.56e-06	1.1e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	1.55e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	1.55e-06	1.09e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CREBBP—urinary bladder cancer	1.54e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	1.54e-06	1.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—urinary bladder cancer	1.54e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	1.53e-06	1.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—urinary bladder cancer	1.53e-06	1.08e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—urinary bladder cancer	1.52e-06	1.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—urinary bladder cancer	1.51e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—urinary bladder cancer	1.5e-06	1.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—urinary bladder cancer	1.49e-06	1.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—urinary bladder cancer	1.48e-06	1.05e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	1.48e-06	1.04e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—urinary bladder cancer	1.47e-06	1.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—urinary bladder cancer	1.45e-06	1.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	1.44e-06	1.02e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—urinary bladder cancer	1.44e-06	1.01e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—urinary bladder cancer	1.43e-06	1.01e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—urinary bladder cancer	1.42e-06	1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—urinary bladder cancer	1.41e-06	9.96e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—urinary bladder cancer	1.38e-06	9.71e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—urinary bladder cancer	1.37e-06	9.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—urinary bladder cancer	1.37e-06	9.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—urinary bladder cancer	1.37e-06	9.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—urinary bladder cancer	1.33e-06	9.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.32e-06	9.28e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	1.31e-06	9.24e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—urinary bladder cancer	1.3e-06	9.17e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—urinary bladder cancer	1.28e-06	9.05e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—urinary bladder cancer	1.28e-06	9.03e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—urinary bladder cancer	1.27e-06	8.96e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—urinary bladder cancer	1.26e-06	8.91e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—urinary bladder cancer	1.26e-06	8.91e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	1.25e-06	8.84e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	1.25e-06	8.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	1.23e-06	8.66e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	1.23e-06	8.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.22e-06	8.63e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.21e-06	8.53e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.21e-06	8.53e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—urinary bladder cancer	1.21e-06	8.52e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	1.18e-06	8.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.16e-06	8.17e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.14e-06	8.02e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—urinary bladder cancer	1.13e-06	7.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-06	7.82e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—urinary bladder cancer	1.1e-06	7.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—urinary bladder cancer	1.09e-06	7.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.07e-06	7.54e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—urinary bladder cancer	1.05e-06	7.41e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—urinary bladder cancer	1.05e-06	7.41e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-06	7.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	1.04e-06	7.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	1.01e-06	7.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—urinary bladder cancer	9.32e-07	6.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—urinary bladder cancer	8.91e-07	6.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.68e-07	6.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.33e-07	5.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.83e-07	4.81e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.95e-07	4.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.68e-07	4e-06	CbGpPWpGaD
